Skip to main content


Featured Article
Researchers investigated whether modifying the dosages of renin-angiotensin-aldosterone system inhibitors negatively impacts the management of hyperkalemia risk as well as cardiorenal outcomes.
“Hyperkalemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction because it limits the use of effective drugs,” researchers wrote.


James J. Matera, DO, nephrologist and vice president of Medical Affairs at CentraState Medical Center in Freehold, New Jersey, recently discussed the challenges of managing hyperkalemia in patients with comorbid CKD and cardiometabolic disease, as…
Managing hyperkalemia is complex and current options are limited; new therapies may address treatment gap.
  New Treatment for Hyperkalemia Current therapy options are limited and there is an increased risk of drug–drug interactions when patients take >1 potassium increasing drug. Hyperkalemia is defined as elevated serum potassium concentrations…
Back to Top